Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer
Citations
373 citations
144 citations
143 citations
Cites result from "Reduction in Physician Reimbursemen..."
...Elliott et al found that for the appropriate group of patients with metastatic disease, use of GnRH agonists did not change after MMA implementation but for males with very low-risk cancers, among whom there was a large decrease.(42) Additional studies were also able to evaluate cost implications, showing that payments to physicians for GnRH agonists decreased substantially between 2003 and 2005....
[...]
116 citations
References
11 citations
"Reduction in Physician Reimbursemen..." refers background in this paper
...The federal government reduced reimbursements for androgen suppression therapy (AST) by 64% between 2004 and 2005 as part of the 2003 Medicare Modernization Act, but whether this reduction resulted in decreased use of AST for prostate cancer is unknown....
[...]
...The 2003 Medicare Modernization Act reduced reimbursements for AST by 64% between 2004 and 2005, but the effect of this large reduction on use of AST is unknown....
[...]
...Faced with rising costs of AST, the federal government reduced AST reimbursement by 64% between 2004 and 2005 as part of the 2003 Medicare Modernization Act (17)....
[...]
...Because payment for other chemotherapeutic agents was also reduced under the Medicare Modernization Act, this investigation is highly relevant to the current health-care reform debate as it pertains to cancer care....
[...]
9 citations
"Reduction in Physician Reimbursemen..." refers background in this paper
...Reimbursement for the drug itself was changed from paying 95% of the average wholesale price through 2003 to 80%–85% of the average wholesale price in 2004 to 106% of the average sales price in 2005 ($190 per 1-month depot in 2005) (32)....
[...]